SCHEDULE: UBS Asset Management Discloses 5.84% Stake in Molecular Partners AG After Filing Delay

UBS Asset Management has disclosed a 5.84% beneficial ownership stake in Molecular Partners AG, with the filing delayed due to systems integration issues following the UBS/Credit Suisse merger.

Summary

• UBS Asset Management (UBS AM), a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC and an aggregation unit within the Asset Management business division of UBS Group AG, has reported beneficial ownership of 2,144,607 common shares in Molecular Partners AG.
• This stake represents 5.84% of Molecular Partners AG's common shares.
• The event triggering this filing occurred on September 30, 2024, when UBS AM's combined positions exceeded the reportable threshold.
• The filing was signed and submitted on July 17, 2025, with the delay attributed to an inadvertent data issue related to UBS / Credit Suisse systems integration, which has since been identified and resolved.
• UBS AM holds sole voting power over 2,086,452 shares and shared dispositive power over all 2,144,607 shares.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership by a large institutional investor. While the acquisition of a significant stake could be viewed positively, the substantial delay in filing due to internal data issues introduces a compliance concern, leading to a neutral overall sentiment.

Positives

• The disclosure of a significant 5.84% stake by a major financial institution like UBS Asset Management could be interpreted as a vote of confidence in Molecular Partners AG.
• The internal data issue that caused the filing delay has been identified and resolved, suggesting improved internal controls and data management.

Negatives

• A significant delay occurred in filing this Schedule 13G, with the event date being September 30, 2024, and the filing date being July 17, 2025, indicating a lapse in regulatory compliance.

Risks

• Potential regulatory scrutiny or penalties for UBS Group AG due to the substantial delay in filing the required Schedule 13G.
• Operational risks related to data integrity and systems integration, as evidenced by the 'inadvertent data issue' stemming from the UBS / Credit Suisse merger.

Future Outlook

NA

Industry Context

This filing is a disclosure of an institutional investor's stake and does not provide broader industry context or trends, though it indicates institutional interest in Molecular Partners AG.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a major institutional investor like UBS AM could influence investor perception and potentially the stock price of Molecular Partners AG. The delay in disclosure might raise questions about transparency and timely reporting.

Key Dates

Keywords

Molecular Partners AG, UBS Asset Management, UBS Group AG, Schedule 13G, Beneficial Ownership, Common Shares, SEC Filing, Institutional Investor, Shareholding